GlassScriptPhysician profile
Syed Hammad Alam
NPI 1275081697
$3,192.78
in general payments reported to CMS, 2019-2025
25 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $307 · 2023: $815 · 2024: $910 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.81 | 2022-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $367.74 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $260.76 | 2023-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $250.54 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $249.95 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $209.35 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $152.94 | 2022-2024 | Veltassa |
| Ani Pharmaceuticals, INC. | $146.89 | 2024-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $123.91 | 2022-2025 | |
| Akebia Therapeutics INC | $122.63 | 2024 | Vafseo |
| Amgen INC. | $122.39 | 2021-2025 | Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $122.35 | 2021-2024 | Rayaldee |
| Medtronic, INC. | $116.23 | 2025 | Symplicity G3 |
| Alexion Pharmaceuticals, INC. | $110.93 | 2022-2024 | Soliris |
| Mallinckrodt Hospital Products INC. | $69.47 | 2024 | Terlivaz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $68.71 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $65.98 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $53.31 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $52.92 | 2024-2025 | Shingrix, Arexvy, Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.80 | 2025 | |
| Nxstage Medical, INC. | $20.62 | 2023 | Nxstage System One, Liberty Select Cycler |
| Apellis Pharmaceuticals, INC. | $19.53 | 2025 | Empaveli |
| Idorsia Pharmaceuticals US INC | $18.89 | 2025 | Tryvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.89 | 2025 | Jardiance |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Hammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.